Peregrine Capital Management’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.32M | Buy |
456,656
+53,515
| +13% | +$975K | 0.25% | 108 |
|
|
2025
Q1 | $8M | Sell |
403,141
-33,056
| -8% | -$656K | 0.27% | 102 |
|
|
2024
Q4 | $7.48M | Buy |
436,197
+15,423
| +4% | +$265K | 0.22% | 123 |
|
|
2024
Q3 | $8.41M | Sell |
420,774
-185,459
| -31% | -$3.71M | 0.25% | 102 |
|
|
2024
Q2 | $6.78M | Sell |
606,233
-208,811
| -26% | -$2.33M | 0.2% | 177 |
|
|
2024
Q1 | $5.38M | Sell |
815,044
-67,939
| -8% | -$448K | 0.15% | 231 |
|
|
2023
Q4 | $3.99M | Buy |
+882,983
| New | +$3.99M | 0.12% | 238 |
|
|
2021
Q2 | – | Sell |
-121,657
| Closed | -$214K | – | 337 |
|
|
2021
Q1 | $214K | Buy |
+121,657
| New | +$214K | ﹤0.01% | 292 |
|